N. Szarvas

Fluorescent enzyme-coupled activity assay for phenylalanine ammonia-lyases

Csaba Paizs, M. Toșa, L. Bencze, 2020, Scientific Reports.

Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments

B. Győrffy, G. Munkácsy, Zsófia Pénzváltó, 2016, Molecular therapy. Nucleic acids.

Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.

A. Blom, B. Villoutreix, Á. Szilágyi, 2015, Molecular Immunology.

Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.

Á. Szilágyi, Z. Prohászka, A. Szabó, 2016, Molecular immunology.

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis

Z. Gucev, V. Tasic, L. Szeifert, 2014, Italian Journal of Pediatrics.

Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.

A. Blom, B. Villoutreix, Á. Szilágyi, 2015, Molecular immunology.